Technical Data Sheet

InVivoSIM anti-human SLAMF7 (Elotuzumab Biosimilar)

Attention: Use of this product constitutes an agreement to Bio X Cell's Terms and Conditions which are included with this product in print and can also be found at https://bioxcell.com/terms-and-conditions.

Lot Specific Information

Lot Number: **Lot Specific***
Volume: **Lot Specific***
Concentration: **Lot Specific* (generally 4 to 11 mg/ml) ***
Total Protein: **Lot Specific***

*This information will be noted on the certificate of analysis that ships with this product.

Product Information

Catalog Number:	**SIM0041**
Clone:	**Elotuzumab**
Isotype:	Human IgG1, κ
Recommended Isotype Control(s):	RecombiMAb human IgG1 isotype control, anti-hen egg lysozyme
Recommended Dilution Buffer:	InVivoPure pH 7.0 Dilution Buffer
Mutations:	E356D/M358L
Immunogen:	Human SLAMF7
Reported Applications:	*in vivo* functional assays *in vitro* functional assays ELISA Western blot Immunoprecipitation Flow cytometry
Formulation:	PBS, pH 7.0 Contains no stabilizers or preservatives
Endotoxin:	≤0.5EU/mg (≤0.0005EU/μg) Determined by LAL gel clotting assay
Purity:	≥95% Determined by SDS-PAGE
Sterility:	0.2 μm filtration
Production:	Purified from cell culture supernatant in an animal-free facility
Aggregation:	<5% Determined by SEC
RRID:	
Molecular Weight:	150 kDa

Murine Pathogen Test Results

Mouse Norovirus: Negative, Mouse Parvovirus: Negative, Mouse Minute Virus: Negative, Mouse Hepatitis Virus: Negative, Reovirus Screen: Negative, Lymphocytic Choriomeningitis virus: Negative, Lactate Dehydrogenase-Elevating Virus: Negative, Mouse Rotavirus: Negative, Theiler's Murine Encephalomyelitis: Negative, Ectromelia/Mousepox Virus: Negative, Hantavirus: Negative, Polyoma Virus: Negative, Mouse Adenovirus: Negative, Sendai Virus: Negative, Mycoplasma Pulmonis: Negative, Pneumonia Virus of Mice: Negative, Mouse Cytomegalovirus: Negative, K Virus: Negative

Description

This non-therapeutic biosimilar antibody uses the same variable regions as the therapeutic antibody Elotuzumab, making it ideal for research use. Elotuzumab is a humanized monoclonal antibody that reacts with the cell surface glycoprotein CD319, which is commonly known as signaling lymphocytic activation molecule family member 7 (SLAMF7). SLAMF7 is highly expressed on myeloma cells, and in normal tissues, its expression is reported in natural killer (NK) cells, plasma cells, spleen

cells, lymph nodes, peripheral blood leukocytes, bone marrow cells, etc. SLAMF7 is suggested to interact with SH2D1A, SH2D1B, PTPN6/SHP-1, PTPN11/SHP-2, INPP5D/SHIP1, CSK, and FYN proteins. Functionally, SLAMF7 is a self-ligand receptor of the SLAM family, and it is involved in the regulation and interconnection of both innate and adaptive immunity. Elotuzumab directly activates NK cells through both the SLAMF7 pathway and Fc receptor signaling. Elotuzumab also increases the expression of CD69 (on NK cells) and enhances IFN γ secretion and granzyme B biosynthesis, independent of Fc receptor signaling. In myeloma cells, based on in vitro studies, Elotuzumab is reported to target SLAMF7 and facilitate the interaction with NK cells for promoting myeloma cell death through the antibody-dependent cellular cytotoxicity (ADCC) mechanism. Elotuzumab disrupts the cell adhesion-mediated mechanisms of drug resistance in multiple myeloma cells by inhibiting their binding to bone marrow stromal cells in vitro. Elotuzumab is shown to reduce the growth of SLAMF7+ human multiple myeloma OPM2 xenografts in mice. Experiments involving in vitro as well as in vivo preclinical models demonstrated that a combination of Elotuzumab with the thalidomide derivative lenalidomide leads to enhanced activation of NK cells and increased anti-tumor activity.

Storage

Store at the stock concentration at 4°C . **Do not freeze.**
It is not uncommon for a floccule or precipitate to appear during storage. The floccule is typically buffer salts precipitating out of solution or a small bit of protein aggregation. For information on how to remove floccules or precipitates see our FAQ's at https://bioxcell.com/faqs.

Protocol Information


Since applications vary, each investigator should use the application references as a guide to help estimate the appropriate dose or concentration. The dose or concentration can be further optimized experimentally in a dose response or titration experiment.

Application References

For a complete list of references, visit https://bioxcell.com/sim0041?bxcs=9k1b3a#tab_references or scan the QR code below.

Binding Validation

Validation data shown below confirms that this clone binds to its target antigen. For lot specific binding validation data, e-mail technicalservice@bioxcell.com.



Bio X Cell, LLC
https://bioxcell.com
+1-866-787-3444
customerservice@bioxcell.com

Conditions: For research use only. Not for human use. Not for use in diagnostic or therapeutic procedures.
Not for resale.
Bio X Cell, Bio X Cell logo, and all other trademarks are the property of Bio X Cell, LLC © 2025 Bio X Cell, LLC